Maravai LifeSciences Holdings (FRA:MAR) EBIT : €591.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Maravai LifeSciences Holdings EBIT?

Maravai LifeSciences Holdings's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was €-10.6 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was €591.0 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Maravai LifeSciences Holdings's annualized ROC % for the quarter that ended in Mar. 2024 was -9.53%. Maravai LifeSciences Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -18.85%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Maravai LifeSciences Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 56.22%.

Maravai LifeSciences Holdings EBIT Historical Data

The historical data trend for Maravai LifeSciences Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maravai LifeSciences Holdings EBIT Chart

Maravai LifeSciences Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

21.70

92.42

496.51

539.86

608.55

Maravai LifeSciences Holdings Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															6.83	-5.85	-8.36	615.84	-10.62

Competitive Comparison of Maravai LifeSciences Holdings's EBIT

For the Biotechnology subindustry, Maravai LifeSciences Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Maravai LifeSciences Holdings's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Maravai LifeSciences Holdings's EV-to-EBIT falls into.

Maravai LifeSciences Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €591.0 Mil.

Maravai LifeSciences Holdings (FRA:MAR) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Maravai LifeSciences Holdings's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-73.868 * ( 1 - -1.21% )	/	( (785.222	+	782.965)	/ 2 )
=	-74.7618028	/	784.0935
=	-9.53 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1363.992	-	51.53	-	( 527.24	-	max(0, 80.208	-	641.819	+	527.24	))
=	785.222

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1329.07	-	29.349	-	( 516.756	-	max(0, 54.3	-	614.453	+	516.756	))
=	782.965

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Maravai LifeSciences Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-42.484	/	( ( (204.166 + max(45.132, 0))	+	(148.698 + max(52.815, 0)) )	/	2 )
=	-42.484	/	( ( 249.298	+	201.513 )	/	2 )
=	-42.484	/	225.4055
=	-18.85 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(50.073	+	47.131	+	16.35)	-	(51.53	+	5.058	+	11.834)
=	45.132

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(33.75	+	45.858	+	15.472)	-	(29.349	+	3.849	+	9.067)
=	52.815

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Maravai LifeSciences Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	591.005	/	1051.219
	=	56.22 %

Maravai LifeSciences Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Maravai LifeSciences Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Maravai LifeSciences Holdings (FRA:MAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maravai LifeSciences Holdings Inc (FRA:MAR) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

MRVI:USA MRVI:Mexico MAR:Germany

Address

10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121

Website

https://www.maravai.com

Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.